Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00066326 · ClinicalTrials.gov registry record · Phase 1
Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia
A Phase 1 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00066326: Completed Phase 1 study, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT00066326 is a Phase 1 study that has completed, run by Barbara Ann Karmanos Cancer Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00066326, a Phase 1 study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy such as 17-N-allylamino-17-demethoxygeldanamycin use different ways to stop cancer cells from dividing so they stop growing or die. Combining imatinib mesylate with chemotherapy may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin when given together with imatinib mesylate in treating patients with chronic myelogenous leukemia.
Interventions
- DRUG imatinib mesylate
- DRUG tanespimycin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-06 |
| Est. Completion | 2005-09 |
| Phase | Phase 1 |
What the finished NCT00066326 record still lists
NCT00066326 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which imatinib mesylate is the first listed.
NCT00066326 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00066326 about?
NCT00066326 is a clinical study titled "Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia". RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy such as 17-N-allylamino-17-demethoxygeldanamycin use different ways to stop cancer cells from dividing so they stop growing or die. Combining imatinib...
What is the current status of trial NCT00066326?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-06. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00066326?
The interventions under investigation include: imatinib mesylate (DRUG), tanespimycin (DRUG).
Who is sponsoring clinical trial NCT00066326?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia